Publications by authors named "Virginia Andreotti"

Claim this Profile
A
Assessing Determinants of Response to PARP Inhibition in Germline Mutant Melanoma.
Eleonora Allavena, Michela Croce, Bruna Dalmasso, Cecilia Profumo, Valentina Rigo, Virginia Andreotti

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature.
Gabriele Gaggero, Teresa Battaglia, Virginia Andreotti, Andrea Rossi, Marta Ingaliso

Turk Arch Pediatr· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Variants: A Critical Perspective on Tumor Predisposition Syndrome.
Virginia Andreotti, Irene Vanni, Lorenza Pastorino, Paola Ghiorzo, William Bruno

Genes (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.
Irene Vanni, Lorenza Pastorino, Enrica Teresa Tanda, Virginia Andreotti, Bruna Dalmasso

Int J Mol Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma.
Lorenza Pastorino, Bruna Dalmasso, Eleonora Allavena, Irene Vanni, Filippo Ugolini, Virginia Andreotti

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.
Alberto Puccini, Marta Ponzano, Bruna Dalmasso, Irene Vanni, Annalice Gandini, Virginia Andreotti

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
Vera V Grinkevich, Aparna Vema, Karin Fawkner, Natalia Issaeva, Virginia Andreotti

Front Mol Biosci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: A Mutation Identified Through Next-Generation Sequencing in a Birt-Hogg-Dubè Syndrome Family.
Erika Bandini, Ilaria Cangini, Valentina Arcangeli, Mila Ravegnani, Virginia Andreotti

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
Irene Vanni, Milena Casula, Lorenza Pastorino, Antonella Manca, Bruna Dalmasso, Virginia Andreotti

Diagn Pathol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current State of Target Treatment in BRAF Mutated Melanoma.
Enrica Teresa Tanda, Irene Vanni, Andrea Boutros, Virginia Andreotti, William Bruno

Front Mol Biosci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.
Irene Vanni, Enrica Teresa Tanda, Bruna Dalmasso, Lorenza Pastorino, Virginia Andreotti

Front Mol Biosci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.
Irene Vanni, Enrica Teresa Tanda, Francesco Spagnolo, Virginia Andreotti, William Bruno

Front Mol Biosci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.
Marianna Avitabile, Mariangela Succoio, Alessandro Testori, Antonella Cardinale, Zalman Vaksman, Virginia Andreotti

Carcinogenesis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, and .
Lorenza Pastorino, Virginia Andreotti, Bruna Dalmasso, Irene Vanni, Giulia Ciccarese

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients.
Giulia Ciccarese, Bruna Dalmasso, William Bruno, Paola Queirolo, Lorenza Pastorino, Virginia Andreotti

J Transl Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Bruna Dalmasso, Lorenza Pastorino, Giulia Ciccarese, Virginia Andreotti, Federica Grillo

J Am Acad Dermatol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.
Sebastian Walpole, Antonia L Pritchard, Colleen M Cebulla, Robert Pilarski, Meredith Stautberg, Virginia Andreotti

J Natl Cancer Inst· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.
William Bruno, Claudia Martinuzzi, Bruna Dalmasso, Virginia Andreotti, Lorenza Pastorino

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.
William Bruno, Claudia Martinuzzi, Bruna Dalmasso, Virginia Andreotti, Lorenza Pastorino

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development.
William Bruno, Virginia Andreotti, Alessandra Bisio, Lorenza Pastorino, Giuseppe Fornarini

PLoS One· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
William Bruno, Claudia Martinuzzi, Virginia Andreotti, Lorenza Pastorino, Francesco Spagnolo

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.
Claudia Martinuzzi, Lorenza Pastorino, Virginia Andreotti, Anna Garuti, Michele Minuto

Endocrine· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma.
Virginia Andreotti, Alessandra Bisio, Brigitte Bressac-de Paillerets, Mark Harland, Odile Cabaret

Pigment Cell Melanoma Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
William Bruno, Lorenza Pastorino, Paola Ghiorzo, Virginia Andreotti, Claudia Martinuzzi

J Am Acad Dermatol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 5'-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding.
Alessandra Bisio, Elisa Latorre, Virginia Andreotti, Brigitte Bressac-de Paillerets, Mark Harland

Oncotarget· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis